We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Drug Industry Faces Vast Antitrust Probe

Law360 (March 30, 2006, 12:00 AM EST) -- As part of a wide probe into anticompetitive practices in the prescription drug industry, the Federal Trade Commission will subpoena nearly 200 pharmaceutical companies to determine whether they are stifling competition by releasing authorized generics of brand-name drugs to stave off generic challengers made by competitors.

Under the Hatch-Waxman Act, the first generic maker to challenge patents on a drug wins six months of exclusive marketing rights. After the exclusivity period expires, other challengers can seek approval for generic versions.

But under "authorized generics" agreements, a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.